Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Inhibition of ERK1/2 Reverses Venetoclax-Induced Autophagy to Overcome Resistance in Acute Myeloid Leukemia

Priyanka Sharma, Sujan Piya, Natalia Baran, Muharrem Muftuoglu, Mahesh Basyal, Vivian Ruvolo, Christopher J. Hindley, Kim-Hien Dao, Martin Sims, Michael Andreeff, Gautam Borthakur

Blood (2022) 140 (Supplement 1): 3093–3094.

https://doi.org/10.1182/blood-2022-165552

Published: 2022

Journal Articles

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Altering Drp1-Dependent Mitochondrial Fission and Metabolism

Priyanka Sharma, Sujan Piya, Natalia Baran, Anna Zal, Christopher J. Hindley, Kim-Hien Dao, Martin Sims, Tomasz Zal, Vivian Ruvolo, Michael Andreeff, Gautam Borthakur

Blood (2022) 140 (Supplement 1): 8789–8790.

https://doi.org/10.1182/blood-2022-167171

Published: 2022

Journal Articles

ERK1/2 Inhibition Overcomes Resistance in Acute Myeloid Leukemia (AML) and Alters Mitochondrial Dynamics

Priyanka Sharma, Sujan Piya, Huaxian Ma, Natalia Baran, Malgorzata Anna Zal, Christopher J. Hindley, Kim-Hien Dao, Martin Sims, Tomasz Zal, Vivian Ruvolo, Michael Andreeff, Gautam Borthakur

Blood (2021) 138 (Supplement 1): 3338.

https://doi.org/10.1182/blood-2021-151579

Published: 2021

Journal Articles

Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models

Christopher J. Hindley, PhD, Lynsey Fazal, BSc, Joanne M. Munck, PhD, Vanessa Martins, BSc, Alpesh D. Shah, MSci, Nicola E. Wilsher, PhD, Nicola G. Wallis, PhD, Harold N. Keer, MDPhD, John F. Lyons, PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-139175

Published: 2020